查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2028 年的体内毒理学市场预测——按产品、实验室、研究类型、毒性终点、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1273269

到 2028 年的体内毒理学市场预测——按产品、实验室、研究类型、毒性终点、最终用户和地区进行的全球分析

In Vivo Toxicology Market Forecasts to 2028 - Global Analysis By Product, Testing Facility, Test Type, Toxicity End Point, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC，全球体内毒理学市场规模将在 2022 年和 2028 年分别达到 55.6 亿美元和 76 亿美元，在预测期内以 5.5% 的复合年增长率增长。预计达到7000万美元。

生物毒理学研究各种药物对生物体（通常是动物）的毒性。 这与使用计算机模型和细胞係等非生命技术的体外毒理学相反。 此类研究调查化学品和药物如何影响活体动物的行为和健康。 这些数据将用于製造有助于预防或治疗某些人类疾病（例如癌症和阿尔茨海默病）的重要药物。

根据美国疾病控制和预防中心 (CDC) 的数据，到 2021 年，美国将有大约 1820 万 20 岁及以上的成年人患有冠状动脉疾病 (CAD)。 心脏病是美国人死亡的主要原因。

市场动态：

驱动程序

原始体内毒性试验

随着体外和计算机毒性测试等替代方法的出现，一些毒性研究现在正在实验室中进行。 但有些试验只能在体内进行，如对儿童的致癌性、致畸性、生殖毒性、致突变性、神经毒性等发育毒性。 对药物致癌毒性试验的日益重视有望促进体内毒性试验动物模型的引入。 据癌症研究所称，目前正在进行长期的囓齿动物致癌性研究，以评估药物对人类的致癌风险，这正在推动市场。

约束

动物试验的替代方法

预计在没有动物试验的情况下使用体外模型进行产品开发会限制体内毒理学行业的发展。 这些模型在毒性研究中被广泛接受，例如人类干细胞、药物、细胞培养模型和高通量测试。 此外，替代毒性测试方法的使用增加可能会减少对动物模型的需求并阻碍市场。

机会

对人源化动物模型的需求不断增长

人性化动物模型是进行临床前研究以更多地了解人类生物学的有用工具。 该模型是通过将人类细胞和组织移植到动物体内并表达人类蛋白质而创建的。 人源化小鼠越来越多地用作癌症、传染病、HIV/AIDS、再生医学和肝炎的研究模型。 越来越重视对人类特异性感染、治疗和疾病的研究，以及对发现药物对人类的真正影响的日益增长的需求，为市场增长提供了广泛的机会。

威胁

动物测试法规和法律

动物保护和福利规章制度的实施导致动物因各种原因受到限制和禁止。 过去五年，许多国家禁止在化妆品中使用动物成分。 此外，美国国立卫生研究院 (NIH) 赞助的研究机构必须遵循公共卫生服务 (PHS) 政策和实验室动物护理研究所 (ILAR) 实验动物护理和使用指南。我们寻求。 研究机构寻求国际实验动物护理评估和认证协会 (AAALAC) 的认证，但这阻碍了市场增长。

COVID-19 的影响：

人们越来越关注 COVID-19 疫苗的开发，预计将为扩大体内毒理学市场创造有利可图的机会。 据世界卫生组织称，目前全球有 20 种疫苗正在研发中，一些处于临床前阶段，另一些已经在进行动物试验。 此外，在 SARS-CoV-2 复製中以小鼠模型为首的 COVID-19 研究中动物模型的有效利用有望推动市场扩张。 儘管大流行带来了前景，但由于动物模型生产商无法满足不断增长的需求，现有供应有限。

慢性期预计在预测期内最大。

由于毒性研究是在至少一种囓齿动物和一种非囓齿动物物种中进行的，因此假设慢性期部分将有良好的生长。 测试物质给药超过 90 天，并定期检查动物。 慢性毒性研究提供了有关受试物质对动物的长期影响的信息，可以推断出受试物质对人体的安全性。 因此，用于长期治疗的药物，如化学治疗剂、抗癌剂、抗惊厥剂、抗高血压剂和抗关节炎剂，需要进行长期毒性研究，从而推动该领域的扩展。

预计免疫毒性部分在预测期内的复合年增长率最高

由于过量服用药物、生物製剂和接触化学品会对免疫系统活动产生不利影响，预计在预测期内，免疫毒性将以最高复合年增长率增长。 接触苯、石棉和卤代芳烃会导致人体免疫抑制。

市场份额最高的地区

预计在预测期内，北美将占据最高的市场份额。 这是因为对个性化药物的高需求是北美市场的主要驱动力，包括美国和加拿大。 此外，加拿大干细胞研究部门的崛起，主要是由于与实施加拿大干细胞战略和行动计划相关的大量支出，也为北美市场做出了贡献。

复合年增长率最高的地区：

由于其蓬勃发展的製药和生物製药行业以及不断增加的研发投资，预计欧洲在预测期内的复合年增长率最高。 然而，由于早期阶段的广泛研究和开发推动了市场，预计该地区的体内毒理学技术活动将会增加。

主要发展：

2023 年 3 月，Charles River 发布了 Apollo(TM)，这是业界领先的基于云的安全平台，用于实时毒性测试数据，该平台当前的功能包括安全评估，旨在支持客户进行毒性测试。

2023 年 2 月，杰克逊实验室与西北大学合作为临床医生开设心臟基因组学课程，西北大学帮助临床医生更好地识别有遗传性心脏病风险的患者，使之成为可能。

2023 年 2 月，Charles River 宣布了一种基于 IgY 的新型 ELISA 试剂盒，用于检测和定量残留宿主细胞蛋白。 这种提高的灵敏度和特异性是由于使用了独特的鸡免疫球蛋白 y (IgY) 抗体。

这份报告提供了什么

  • 区域和国家/地区细分市场份额评估
  • 向新进入者提出战略建议
  • 2020、2021、2022、2025 和 2028 年的综合市场数据
  • 市场驱动因素（市场趋势、制约因素、机遇、威胁、挑战、投资机会、建议）。
  • 根据市场预测在关键业务领域提出战略建议
  • 竞争格局映射关键共同趋势。
  • 公司简介，包括详细的战略、财务状况和近期发展
  • 映射最新技术进步的供应链趋势

免费定制优惠：

购买此报告的客户将获得以下免费定制选项之一：

  • 公司简介
    • 其他市场参与者的综合概况（最多 3 家公司）
    • 主要参与者的 SWOT 分析（最多 3 家公司）
  • 区域细分
    • 根据客户的要求对主要国家/地区的市场估计/预测/复合年增长率（注意：基于可行性检查）。
  • 竞争基准
    • 根据产品组合、区域影响力和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第2章前言

  • 概览
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 调查来源
    • 主要研究来源
    • 二级研究来源
    • 假设

第3章市场趋势分析

  • 司机
  • 约束因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第 4 章波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第 5 章全球体内毒理学市场：按产品分类

  • 消耗品
  • 设备
    • 动物模型
      • 大鼠模型
      • 小鼠模型
      • 其他动物模型
  • 其他产品

第 6 章全球体内毒理学市场：按实验室分类

  • 合同测试设施
  • 内部测试设施

第 7 章全球体内毒理学市场：按测试类型

  • 亚急性
  • 急性
  • 亚慢性
  • 慢性
  • 其他测试类型

第 8 章全球体内毒理学市场：按毒性终点分类

  • 全身毒性
  • 致癌性
  • 遗传毒性
  • 免疫毒性
  • 发育和生殖毒性 (DART)
  • 其他毒性终点

第 9 章全球体内毒理学市场：按最终用户分类

  • 製药和生物技术公司
  • 委託研究机构
  • 学术研究机构
  • 其他最终用户

第 10 章全球体内毒理学市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东和非洲地区

第11章主要发展

  • 合同、伙伴关係、协作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第12章公司简介

  • The Jackson Laboratory
  • Charles River Laboratories
  • Taconic Biosciences
  • Janvier Labs
  • Thermo Fisher Scientific
  • Waters Corporation
  • Danaher Corporation
  • Shimadzu Corporation
  • Agilent Technologies
  • PerkinElmer
  • Merck KGaA
  • GE Healthcare
  • genOway
  • Bio-Rad Laboratories
  • Crown Biosciences
  • Harbour BioMed
  • Bruker Corporation
  • TransCure bioServices
Product Code: SMRC22814

According to Stratistics MRC, the Global In Vivo Toxicology Market is accounted for $5.56 billion in 2022 and is expected to reach $7.67 billion by 2028 growing at a CAGR of 5.5% during the forecast period. Vivo toxicology is the study of the toxicity of various medications on a living organism, usually an animal. This is in contrast to in vitro toxicology, which uses non-living technologies like as computer models and cell lines. This type of testing investigates how chemicals and medications affect the behaviour and health of living animals. This data is used in the creation of critical drugs that can help prevent and treat specific human diseases such as cancer and Alzheimer's.

According to the Centers for Disease Control and Prevention (CDC), in 2021, around 18.2 million adults aged 20 and older had coronary artery disease (CAD) in the United States. Heart disease is the leading cause of death among people in the United States.

Market Dynamics:

Driver:

Unique In vivo toxicological tests

Several toxicological tests are now carried out in laboratories, thanks to the emergence of alternative methodologies such as in vitro and in silico toxicity testing. Certain assays, however, are only available in vivo, such as tests for carcinogenicity, developmental including teratogenicity in children and reproductive toxicity, mutagenicity, and neurotoxicity. The increased emphasis on drug carcinogenic toxicity studies is likely to drive the adoption of animal models for in vivo toxicology testing. According to the Cancer Research Institute long term rodent carcinogenicity studies are currently being investigated in order to assess the carcinogenic risk of medications in humans which are propelling the market.

Restraint:

Animal testing alternatives

In the non-animal product development, the use of in vitro models is projected to limit the growth of the in vivo toxicology industry. Such models have acquired widespread acceptance in toxicological testing for human stem cells, pharmaceuticals, cell culture models, and high-throughput testing. Furthermore, the growing use of alternative toxicological testing techniques is likely to reduce need for animal models thereby hindering the market.

Opportunity:

Increasing demand for humanised animal models

Humanised animal models are useful instruments for performing preclinical research to learn more about human biology. These models are created by engrafting human cells or tissues into animals, resulting in the expression of human proteins. Humanised mice are increasingly being employed as study models for cancer, infectious illnesses, HIV/AIDS, regenerative medicine, and hepatitis. The rising emphasis on investigating human-specific infections, cures, and diseases, as well as the necessity to discover the actual effects of medications on humans creating wide range of opportunities for the growth of the market.

Threat:

Animal research regulations and laws

The implementation of animal protection and welfare rules and regulations has resulted in restrictive practises and animal bans for a variety of reasons. Many countries have prohibited the use of animals in the cosmetics sector in the last five years. Furthermore, institutes sponsored by the National Institutes of Health (NIH) are expected to follow Public Health Service (PHS) policy and the Institute for Laboratory Animal Research (ILAR) Guide for the Care and Use of Laboratory Animals. Research institutes seek accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC), which halts the market growth.

COVID-19 Impact:

The increased focus on COVID-19 vaccine development is expected to create lucrative chances for the market expansion of in vivo toxicology. According to the WHO, 20 vaccines are now in development around the world, with some in the preclinical stage and others having already entered the animal trial phase. Furthermore, the effective use of animal models in COVID-19 research, notably mice models in SARS-CoV-2 replication, is projected to drive market expansion. Despite the prospects presented by the pandemic, existing supply is limited because to animal model producers inability to fulfil increasing demand.

The chronic segment is expected to be the largest during the forecast period

The chronic segment is estimated to have a lucrative growth, due to toxicity testing are performed on at least one rodent and one non-rodent species. The test substance is administered over a period of more than 90 days, and the animals are examined on a regular basis. A chronic toxicological research gives information regarding the long-term effects of a test chemical in animals, which may then be extrapolated to the test substance's safety in humans. As a result, medications used for long-term therapy, such as chemotherapeutic agents, anti-cancer, anti-convulsive, anti-hypertensive, and anti-arthritic therapies, necessitate long-term toxicity testing, driving sector expansion.

The Immunotoxicity segment is expected to have the highest CAGR during the forecast period

The Immunotoxicity segment is anticipated to witness the highest CAGR growth during the forecast period, due to the unfavourable effects on immune system activities produced by excessive medication exposure, biologics, or chemical compound exposure. Human immunosuppression may result from exposure to benzene, asbestos, and halogenated aromatic hydrocarbons.

Region with highest share:

North America is projected to hold the highest market share during the forecast period owing to the high demand for personalised pharmaceuticals is the primary driver of the North American market which includes the United States and Canada. Furthermore, the rise of the Canadian stem cell research sector, which is primarily driven by large-scale expenditures as a result of the implementation of the Canadian Stem Cell Strategy and Action Plan, is a contributing factor to the North America market.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the region's thriving pharmaceutical and biopharmaceutical industries, as well as the increased investment in R&D. However, due to the extensive R&D in the early stages, which is projected to drive the market, the In Vivo Toxicology technique activities are likely to expand in this region

Key players in the market:

Some of the key players profiled in the In Vivo Toxicology Market include: The Jackson Laboratory, Charles River Laboratories, Taconic Biosciences, Janvier Labs, Thermo Fisher Scientific, Waters Corporation, Danaher Corporation, Shimadzu Corporation, Agilent Technologies, PerkinElmer, Merck KGaA, GE Healthcare, genOway, Bio-Rad Laboratories, Crown Biosciences, Harbour BioMed, Bruker Corporation and TransCure bioServices

Key Developments:

In March 2023, Charles River Launches Apollo™, an industry-leading, secure, cloud-based platform for real-time toxicology study data, the platform's current capabilities are designed to support clients with safety assessment and toxicology studies.

In Feb 2023, The Jackson Laboratory partners with northwestern to create cardiogenomics course for clinicians, with northwestern university will help clinicians better identify patients at risk for genetic cardiac disease.

In Feb 2023, Charles River Launches Novel IgY-based ELISA Kit for the detection and quantitation of residual host cell protein, this increase in sensitivity and specificity can be attributed to the unique chicken immunoglobulin y (IgY) antibodies utilized.

Products Covered:

  • Consumables
  • Instruments
  • Other Products

Testing Facilities Covered:

  • Outsourced Testing Facility
  • In-House Testing Facility

Test Types Covered:

  • Sub-Acute
  • Acute
  • Sub-Chronic
  • Chronic
  • Other Test Types

Toxicity End Points Covered:

  • Systemic Toxicity
  • Carcinogenicity
  • Genotoxicity
  • Immunotoxicity
  • Developmental & Reproductive Toxicity (DART)
  • Other Toxicity Endpoints

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Academic & Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global In Vivo Toxicology Market, By Product

  • 5.1 Introduction
  • 5.2 Consumables
  • 5.3 Instruments
    • 5.3.1 Animal Models
      • 5.3.1.1 Rat Models
      • 5.3.1.2 Mice Models
      • 5.3.1.3 Other Animal Models
  • 5.4 Other Products

6 Global In Vivo Toxicology Market, By Testing Facility

  • 6.1 Introduction
  • 6.2 Outsourced Testing Facility
  • 6.3 In-House Testing Facility

7 Global In Vivo Toxicology Market, By Test Type

  • 7.1 Introduction
  • 7.2 Sub-Acute
  • 7.3 Acute
  • 7.4 Sub-Chronic
  • 7.5 Chronic
  • 7.6 Other Test Types

8 Global In Vivo Toxicology Market, By Toxicity End Point

  • 8.1 Introduction
  • 8.2 Systemic Toxicity
  • 8.3 Carcinogenicity
  • 8.4 Genotoxicity
  • 8.5 Immunotoxicity
  • 8.6 Developmental & Reproductive Toxicity (DART)
  • 8.7 Other Toxicity Endpoints

9 Global In Vivo Toxicology Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical & Biotechnology Companies
  • 9.3 Contract Research Organizations
  • 9.4 Academic & Research Institutes
  • 9.5 Other End Users

10 Global In Vivo Toxicology Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 The Jackson Laboratory
  • 12.2 Charles River Laboratories
  • 12.3 Taconic Biosciences
  • 12.4 Janvier Labs
  • 12.5 Thermo Fisher Scientific
  • 12.6 Waters Corporation
  • 12.7 Danaher Corporation
  • 12.8 Shimadzu Corporation
  • 12.9 Agilent Technologies
  • 12.10 PerkinElmer
  • 12.11 Merck KGaA
  • 12.12 GE Healthcare
  • 12.13 genOway
  • 12.14 Bio-Rad Laboratories
  • 12.15 Crown Biosciences
  • 12.16 Harbour BioMed
  • 12.17 Bruker Corporation
  • 12.18 TransCure bioServices

List of Tables

  • Table 1 Global In Vivo Toxicology Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global In Vivo Toxicology Market Outlook, By Product (2020-2028) ($MN)
  • Table 3 Global In Vivo Toxicology Market Outlook, By Consumables (2020-2028) ($MN)
  • Table 4 Global In Vivo Toxicology Market Outlook, By Instruments (2020-2028) ($MN)
  • Table 5 Global In Vivo Toxicology Market Outlook, By Animal Models (2020-2028) ($MN)
  • Table 6 Global In Vivo Toxicology Market Outlook, By Rat Models (2020-2028) ($MN)
  • Table 7 Global In Vivo Toxicology Market Outlook, By Mice Models (2020-2028) ($MN)
  • Table 8 Global In Vivo Toxicology Market Outlook, By Other Animal Models (2020-2028) ($MN)
  • Table 9 Global In Vivo Toxicology Market Outlook, By Other Products (2020-2028) ($MN)
  • Table 10 Global In Vivo Toxicology Market Outlook, By Testing Facility (2020-2028) ($MN)
  • Table 10 Global In Vivo Toxicology Market Outlook, By Outsourced Testing Facility (2020-2028) ($MN)
  • Table 11 Global In Vivo Toxicology Market Outlook, By In-House Testing Facility (2020-2028) ($MN)
  • Table 12 Global In Vivo Toxicology Market Outlook, By Test Type (2020-2028) ($MN)
  • Table 14 Global In Vivo Toxicology Market Outlook, By Sub-Acute (2020-2028) ($MN)
  • Table 15 Global In Vivo Toxicology Market Outlook, By Acute (2020-2028) ($MN)
  • Table 16 Global In Vivo Toxicology Market Outlook, By Sub-Chronic (2020-2028) ($MN)
  • Table 17 Global In Vivo Toxicology Market Outlook, By Chronic (2020-2028) ($MN)
  • Table 18 Global In Vivo Toxicology Market Outlook, By Other Test Types (2020-2028) ($MN)
  • Table 19 Global In Vivo Toxicology Market Outlook, By Toxicity End Point (2020-2028) ($MN)
  • Table 20 Global In Vivo Toxicology Market Outlook, By Systemic Toxicity (2020-2028) ($MN)
  • Table 21 Global In Vivo Toxicology Market Outlook, By Carcinogenicity (2020-2028) ($MN)
  • Table 22 Global In Vivo Toxicology Market Outlook, By Genotoxicity (2020-2028) ($MN)
  • Table 23 Global In Vivo Toxicology Market Outlook, By Immunotoxicity (2020-2028) ($MN)
  • Table 24 Global In Vivo Toxicology Market Outlook, By Developmental & Reproductive Toxicity (DART) (2020-2028) ($MN)
  • Table 25 Global In Vivo Toxicology Market Outlook, By Other Toxicity Endpoints (2020-2028) ($MN)
  • Table 26 Global In Vivo Toxicology Market Outlook, By End User (2020-2028) ($MN)
  • Table 27 Global In Vivo Toxicology Market Outlook, By Pharmaceutical & Biotechnology Companies (2020-2028) ($MN)
  • Table 28 Global In Vivo Toxicology Market Outlook, By Contract Research Organizations (2020-2028) ($MN)
  • Table 29 Global In Vivo Toxicology Market Outlook, By Academic & Research Institutes (2020-2028) ($MN)
  • Table 30 Global In Vivo Toxicology Market Outlook, By Other End Users (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.